The Role Of Actinium-225 PSMA In The Treatment Of Prostate Cancer

The Role Of Actinium-225 PSMA In The Treatment Of Prostate Cancer

By Donna William | Lifestyle Editor on December 5, 2019
0
prostrate cancer doctor patient save

Today, a large number of methods for diagnostics and treatment of prostate cancer at the early stages have been developed. The percentage of successful treatment is growing every year. However, with metastatic cancer, when the neoplasm has spread beyond the prostate gland and affects other organs and tissues, treatment most often becomes ineffective or simply impossible.

The role of Actinium-225 PSMA in the treatment of prostate cancer

Today, a large number of methods for diagnostics and treatment of prostate cancer at the early stages have been developed. The percentage of successful treatment is growing every year. However, with metastatic cancer, when the neoplasm has spread beyond the prostate gland and affects other organs and tissues, treatment most often becomes ineffective or simply impossible.

How does the Actinium-225 act on PSMA receptors?

The prostate-specific membrane antigen (PSMA) is a receptor on the surface of a prostate carcinoma cell. Revealing PSMA helps to localize tumor tissue precisely and detect prostate cancer metastases. Also, it allows performing targeted radionuclide therapy for men diagnosed with prostate cancer, due to the combination of carrier proteins with the therapeutic radionuclide Actinium-225.

Radionuclide therapy has advantages over other types of radiation therapy due to minor side effects and minimal damage to normal tissues. High irradiation dose in the pathological focus makes it possible to treat distant metastases and disseminated tumors. The technique has no alternatives in patients with a high risk of surgical treatment (after prostatectomy) and drug intolerance, patients with bone metastases and severe pain syndrome.

Medicinal properties of Actinium-225 PSMA therapy

Actinium-225 gained popularity as a therapeutic radionuclide due to the peculiarities of its physical properties, ensuring its high efficiency in prostate cancer treatment. The radiation characteristics of this isotope correspond to the requirements for radiation therapy for prostate cancer, which are creating a necessary concentration in the tumor tissue and providing sufficient Gamma irradiation intensity. PSMA therapy with Actinium-225 considers the volume of the organ and has a gentle effect on the surrounding healthy tissues. In addition, PSMA PET-CT allows us to visualize the tumor ex vivo and, therefore, provide information about its location for the dosimetric measurements.

The technology of Actinium-225 PSMA performing

Treatment with Actinium-225 PSMA in Germany is a well-tolerated targeted therapy without any significant adverse reactions. During treatment, it is necessary to comply with the standard rules of radiation safety, the same for all methods. The drug Actinium-225 is administered as a solution intravenously slowly. The medication is excreted by kidneys during the first 48 hours after the injection. Patients should drink more before and after the administration of the drug.

For foreigners who want to undergo treatment abroad, it is more convenient to use the help of the medical provider Booking Health. Booking Health will assist in organizational matters, as well as in the selection of clinics and qualified specialists. Thanks to more than a decade of experience in the medical tourism field, you will not need to pay a tax for foreigners which will help you save up to 50 % of the total cost of treatment.

Treatment effectiveness

According to currently published data, up to 80% of patients with hormone-resistant forms of metastatic prostate cancer who have undergone the PSMA therapy with Actinium-225 have demonstrated a decrease in PSMA levels by more than 50%.

Thus, radionuclide therapy with Actinium-225 PSMA demonstrates high treatment efficacy in men with mCRPC and is important in the treatment of prostate cancer. Studies show that the technique has a low level of toxicity and is well tolerated by patients with metastatic prostate cancer. During the use of Actinium-225 PSMA in practice, there has been a positive trend in survival rates. A thorough assessment of the clinical efficacy in the combined regimens is carried out, as the technique is applied along with chemotherapy, external radiation therapy, and antiandrogen therapy.

NO COMMENTS

Leave a Comment

To leave a comment anonymously, simple write your thoughts in the comments box below and click the ‘post comment’ button.